405 related articles for article (PubMed ID: 33755262)
1. Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
Shill HA; Zhang N; Driver-Dunckley E; Mehta S; Adler CH; Beach TG
Mov Disord; 2021 Jul; 36(7):1700-1704. PubMed ID: 33755262
[TBL] [Abstract][Full Text] [Related]
2. Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease.
Doty RL; Golbe LI; McKeown DA; Stern MB; Lehrach CM; Crawford D
Neurology; 1993 May; 43(5):962-5. PubMed ID: 8492953
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
Ali F; Martin PR; Botha H; Ahlskog JE; Bower JH; Masumoto JY; Maraganore D; Hassan A; Eggers S; Boeve BF; Knopman DS; Drubach D; Petersen RC; Dunkley ED; van Gerpen J; Uitti R; Whitwell JL; Dickson DW; Josephs KA
Mov Disord; 2019 Aug; 34(8):1144-1153. PubMed ID: 30726566
[TBL] [Abstract][Full Text] [Related]
4. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
Williams DR; Lees AJ
Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379
[TBL] [Abstract][Full Text] [Related]
5. Hyposmia in progressive supranuclear palsy.
Silveira-Moriyama L; Hughes G; Church A; Ayling H; Williams DR; Petrie A; Holton J; Revesz T; Kingsbury A; Morris HR; Burn DJ; Lees AJ
Mov Disord; 2010 Apr; 25(5):570-7. PubMed ID: 20209627
[TBL] [Abstract][Full Text] [Related]
6. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
Quattrone A; Bianco MG; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Tedeschi G; Tessitore A; Cilia R; Morelli M; Nigro S; Vescio B; Arcuri PP; De Micco R; Cirillo M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
Mov Disord; 2022 Jun; 37(6):1272-1281. PubMed ID: 35403258
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients.
Toyoshima Y; Takahashi H; Katada S; Kojima N; Tada M; Tani T; Koike R; Nozawa T; Aida I; Nakajima T; Onodera O; Kakita A
Neuropathology; 2021 Dec; 41(6):450-456. PubMed ID: 34779072
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients.
Sankhla CS; Patil KB; Sawant N; Gupta S
Neurol India; 2016; 64(2):239-45. PubMed ID: 26954800
[TBL] [Abstract][Full Text] [Related]
9. Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism.
Krismer F; Pinter B; Mueller C; Mahlknecht P; Nocker M; Reiter E; Djamshidian-Tehrani A; Boesch SM; Wenning GK; Scherfler C; Poewe W; Seppi K
Parkinsonism Relat Disord; 2017 Feb; 35():36-41. PubMed ID: 27890451
[TBL] [Abstract][Full Text] [Related]
10. Brainstem atrophy in dementia with Lewy bodies compared with progressive supranuclear palsy and Parkinson's disease on MRI.
Müller SJ; Khadhraoui E; Hansen N; Jamous A; Langer P; Wiltfang J; Riedel CH; Bouter C; van Riesen C; Maass F; Bartl M; Lange C; Ernst M
BMC Neurol; 2023 Mar; 23(1):114. PubMed ID: 36944914
[TBL] [Abstract][Full Text] [Related]
11. Video-oculographic biomarkers for evaluating vertical ocular dysfunction in progressive supranuclear palsy.
Quattrone A; Crasà M; Morelli M; Vescio B; Augimeri A; Gramigna V; Quattrone A
Parkinsonism Relat Disord; 2022 Jun; 99():84-90. PubMed ID: 35642995
[TBL] [Abstract][Full Text] [Related]
12. The evolution of diagnosis from symptom onset to death in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to Parkinson's disease (PD).
Swallow DMA; Counsell CE
J Neurol; 2023 Jul; 270(7):3464-3474. PubMed ID: 36971841
[TBL] [Abstract][Full Text] [Related]
13. The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy.
Suzuki M; Hashimoto M; Yoshioka M; Murakami M; Kawasaki K; Urashima M
BMC Neurol; 2011 Dec; 11():157. PubMed ID: 22192419
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of oculomotor disturbances in progressive supranuclear palsy.
Pagonabarraga J; Horta-Barba A; Busteed L; Bejr-Kasem H; Illán-Gala I; Aracil-Bolaños I; Marín-Lahoz J; Pascual-Sedano B; Pérez J; Campolongo A; Izquierdo C; Martinez-Horta S; Sampedro F; Kulisevsky J
Parkinsonism Relat Disord; 2021 Apr; 85():63-68. PubMed ID: 33744691
[TBL] [Abstract][Full Text] [Related]
15. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism.
Williams DR; Warren JD; Lees AJ
J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):652-5. PubMed ID: 17872984
[TBL] [Abstract][Full Text] [Related]
16. When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients.
Koga S; Aoki N; Uitti RJ; van Gerpen JA; Cheshire WP; Josephs KA; Wszolek ZK; Langston JW; Dickson DW
Neurology; 2015 Aug; 85(5):404-12. PubMed ID: 26138942
[TBL] [Abstract][Full Text] [Related]
17. Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis.
Del Prete E; Tommasini L; Mazzucchi S; Frosini D; Palermo G; Morganti R; Pagni C; Tognoni G; Bonuccelli U; Ceravolo R
Neurol Sci; 2021 Apr; 42(4):1483-1490. PubMed ID: 32851538
[TBL] [Abstract][Full Text] [Related]
18. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study.
Litvan I; Campbell G; Mangone CA; Verny M; McKee A; Chaudhuri KR; Jellinger K; Pearce RK; D'Olhaberriague L
Brain; 1997 Jan; 120 ( Pt 1)():65-74. PubMed ID: 9055798
[TBL] [Abstract][Full Text] [Related]
19. A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
Quattrone A; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Morelli M; Nigro S; Vescio B; Bianco MG; Vasta R; Arcuri PP; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
Mov Disord; 2021 Mar; 36(3):681-689. PubMed ID: 33151015
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.
Respondek G; Roeber S; Kretzschmar H; Troakes C; Al-Sarraj S; Gelpi E; Gaig C; Chiu WZ; van Swieten JC; Oertel WH; Höglinger GU
Mov Disord; 2013 Apr; 28(4):504-9. PubMed ID: 23436751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
